Skip to main content
. 2009 Aug 20;284(42):29041–29049. doi: 10.1074/jbc.M109.041749

FIGURE 5.

FIGURE 5.

Quantification of plasma prolyl 4-hydroxylated α-fibrinogen. A, box-and-whisker diagram showing the different plasma levels of αFG-565Hyp in healthy controls (Cont, n = 113) and pancreatic cancer patients (Ca, n = 160). Boxes represent the median values and the 25–75 percentile range. Whiskers indicate the most extreme data point, which is no more than 1.5 times the interquartile range from the boxes. B, box-and-whisker diagram showing the plasma level of αFG-565Hyp in healthy controls (Cont, n = 113) and patients with stage-IA (n = 2), IB (n = 4), IIA (n = 5), IIB (n = 28), III (n = 41), and IV (n = 78) pancreatic cancer. C, box-and-whisker diagram showing the plasma level of αFG-565Hyp in healthy controls (Cont, n = 113) and patients with pancreatic ductal carcinoma (Du, n = 160), chronic pancreatitis (Pa, n = 12), benign pancreatic tumor or cyst (Be, n = 37), bile duct cancer (Bi, n = 25), cholecystitis (Cy, n = 22), hepatocellular carcinoma (He, n = 14), esophageal cancer (Es, n = 10), gastric cancer (St, n = 147), and colorectal cancer (Co, n = 145).

HHS Vulnerability Disclosure